Full history for every metric is available with a Kvantra account
Klotho Neurosciences, Inc. (KLTO)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -7 | -15 | |||||
| Net profit | $m | - | -1 | -1 | -1 | -6 | -11 | -22 |
| EPS reported | $ | -0.22 | -0.34 | |||||
| Operating cashflow per share | $ | -0.12 | -0.10 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.12 | -0.10 | |||||
| Free cash flow | $m | -6 | -10 | |||||
| Net debt | $m | -7 | -10 | |||||
| Book value equity | $m | 9 | - | |||||
| Book value per share | $ | 0.20 | - | |||||
| Number of shares | m | 48.49 | 93.73 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.48 | 0.69 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -2.39 | -2.09 | |||||
| EV/EBITDA LTM | x | -0.96 | -0.67 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -75.30% | -62.10% | |||||
| FCF Yield | % | -41.80% | -47.81% | |||||
| Quality | ||||||||
| ROE | % | -111.50% | -108.82% | |||||
| ROIC | % | -75.09% | -25.34% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | -32.60 | |||||
| Net Debt/EBITDA | x | 1.00 | 0.63 | |||||
| EBIT/Net interest | x | -3.09 | -5.13 | |||||
| Net debt/market cap | % | -51.21% | -48.35% | |||||
| Net debt/Equity | x | -0.76 | - | |||||
| Gross debt/equity | x | 0.00 | - | |||||
Company overview
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Klotho Neurosciences, Inc. (KLTO)
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free